Legend Biotech reports results from Phase 2 CARTITUDE-2 Cohort D Study

Legend Biotech Corporation announced results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response after front-line autologous stem cell transplant experienced deep and durable responses following a single infusion of CARVYKTI with or without lenalidomide maintenance. These data were presented as an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting and will also be shared as an encore oral presentation at the 2024 European Hematology Association Congress. CARVYKTI is the first and only B-cell maturation antigen-targeted therapy approved for the treatment of patients with relapsed/refractory multiple myeloma as early as after first relapse. “Patients who achieve a less than complete response following ASCT may experience less durable response with future treatments,” said Melissa Alsina, M.D., Head Myeloma BMT-CI Program, H. Lee Moffitt Cancer Center, and Research Institute. The outcomes from this study showed encouraging efficacy results and indicated the potential benefit of CARVYTKI in this patient population.” At a median follow-up of 22 months, patients treated with CARVYKTI demonstrated a 94% overall response rate with all 16 patients achieving a CR or better. Of the 15 minimal residual disease-evaluable patients, 80% achieved MRD negativity at the 10-5 threshold. The median duration of response was not reached and the median time to first response was one month. Eighteen-month progression-free survival and overall survival rates were 94% each. Safety signals were consistent with the known safety profile of CARVYKTI. All patients had grade 3 or 4 treatment emergent adverse events including neutropenia, lymphopenia, thrombocytopenia, leukopenia, infections, or CRS. One patient had a secondary malignancy of grade 3 myelodysplastic syndromes. No cases of movement and neurocognitive treatment-emergent adverse events/parkinsonism were observed.